Literature DB >> 8566863

Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach.

C S Loh1, A J MacRobert, G Buonaccorsi, N Krasner, S G Bown.   

Abstract

Surgery is the only effective treatment for dysplasia in the gastrointestinal tract with considerable associated morbidity and mortality and is difficult to justify without confirmed malignancy. Photodynamic therapy (PDT) produces localised necrosis, which can be limited to the mucosa. This study examined the mechanical properties of the normal rat stomach after PDT. The aim of this study was to measure the bursting pressure of PDT lesions in the stomach and to assess gastric emptying after producing circumferential mucosal necrosis at the pylorus by PDT. Two photosensitising agents were used--5-aminolaevulinic acid (ALA), and aluminium disulphonated phthalocyanine (A1S2Pc). Normal rats were sensitised and PDT lesions created in the stomach with red light. The bursting pressure was measured and compared with that in thermal control lesions. In further experiments, circumferential mucosal necrosis was produced at the pylorus, and animals observed for subsequent eating and weight gain. It was found that gastric bursting pressure was reduced after thermal injury, but not at any time after PDT (with A1S2Pc, but not ALA, adhesive omental reinforcement was required to maintain the gastric wall strength at one week). For the pyloric lesions, gastric emptying was permanently impaired using A1S2Pc, but with low dose ALA (20 mg/kg) had returned to normal by three days. With ALA, but not A1S2Pc, necrosis could be limited to the mucosa. In conclusion, using ALA, selective ablation of the gastric mucosa is possible, which does not reduce the strength of the stomach and only temporarily delays gastric emptying. PDT is a promising technique for the circumferential ablation of dysplastic mucosa.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566863      PMCID: PMC1382982          DOI: 10.1136/gut.38.1.71

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  35 in total

1.  Aluminum sulfonated phthalocyanine distribution in rodent tumors of the colon, brain and pancreas.

Authors:  C J Tralau; H Barr; D R Sandeman; T Barton; M R Lewin; S G Bown
Journal:  Photochem Photobiol       Date:  1987-11       Impact factor: 3.421

2.  The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury.

Authors:  H Barr; C J Tralau; P B Boulos; A J MacRobert; R Tilly; S G Bown
Journal:  Photochem Photobiol       Date:  1987-11       Impact factor: 3.421

3.  Regulation of porphyrin synthesis.

Authors:  J Marriott
Journal:  Biochem Soc Symp       Date:  1968

4.  Porphyrin and haem biosynthesis and its control.

Authors:  C Rimington
Journal:  Acta Med Scand Suppl       Date:  1966

5.  Skin photosensitivity: duration and intensity following intravenous hematoporphyrin derivates, HpD and DHE.

Authors:  N Razum; O J Balchum; A E Profio; F Carstens
Journal:  Photochem Photobiol       Date:  1987-11       Impact factor: 3.421

6.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

7.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.

Authors:  J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

8.  Mouse skin photosensitivity with dihaematoporphyrin ether (DHE) and aluminium sulphonated phthalocyanine (AlSPc): a comparative study.

Authors:  C J Tralau; A R Young; N P Walker; D I Vernon; A J MacRobert; S B Brown; S G Bown
Journal:  Photochem Photobiol       Date:  1989-03       Impact factor: 3.421

9.  Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine.

Authors:  J S Nelson; L H Liaw; A Orenstein; W G Roberts; M W Berns
Journal:  J Natl Cancer Inst       Date:  1988-12-21       Impact factor: 13.506

10.  Photodynamic therapy in the normal rat colon with phthalocyanine sensitisation.

Authors:  H Barr; C J Tralau; A J MacRobert; N Krasner; P B Boulos; C G Clark; S G Bown
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

View more
  5 in total

1.  Photodynamic therapy in gastroenterology.

Authors:  S G Bown; C E Millson
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Safety and delivery efficiency of a photodynamic treatment of the lungs using indocyanine green and extracorporeal near infrared illumination.

Authors:  Giulia Kassab; Vsevolod Cheburkanov; Jace Willis; Madeleine G Moule; Cristina Kurachi; Vladislav Yakovlev; Jeffrey D Cirillo; Vanderlei S Bagnato
Journal:  J Biophotonics       Date:  2020-08-12       Impact factor: 3.207

3.  Effect of photodynamic therapy on normal fibroblasts and colon anastomotic healing in mice.

Authors:  R Haddad; O Kaplan; E Brazovski; M Rabau; S Schneebaum; A Shnaper; Y Skornick; H Kashtan
Journal:  J Gastrointest Surg       Date:  1999 Nov-Dec       Impact factor: 3.452

4.  Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy.

Authors:  Gary D Mackenzie; Jason M Dunn; C R Selvasekar; C Alexander Mosse; Sally M Thorpe; Marco R Novelli; Stephen G Bown; Laurence B Lovat
Journal:  Lasers Med Sci       Date:  2008-12-05       Impact factor: 3.161

5.  A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus.

Authors:  J M Dunn; G D Mackenzie; M R Banks; C A Mosse; R Haidry; S Green; S Thorpe; M Rodriguez-Justo; A Winstanley; M R Novelli; S G Bown; L B Lovat
Journal:  Lasers Med Sci       Date:  2012-06-15       Impact factor: 3.161

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.